Investigation of a Rotavirus Gastroenteritis Outbreak among Immunosuppressed Patients in a Hospital Setting

Ken Sugata1,2*, Jennifer Hull1, Houping Wang1, Kimberley Foytich1, Sung-Sil Moon1, Yoshiyuki Takahashi1, Seiji Kojima3, Tetsushi Yoshikawa4 and Baoming Jiang1

Abstract

Objective: Rotavirus (RV) is the most common cause of severe dehydrating diarrhoea in healthy infants and young children. The aims of this study were to investigate a RV outbreak in the pediatric hematology and oncology ward and to examine possible associations between immune status and RV infection.

Patients and methods: Twenty-eight children (19 boys and 9 girls) who were hospitalized for treatment of hematological malignancy and solid organ tumor during the RV outbreak were enrolled in this study. Fourteen of the 28 patients developed RV gastroenteritis (GE) during the observation period. RV antigen and RV IgG and IgA were measured by enzyme-linked immunosorbent assays. RV G and P types were determined by reverse transcriptase-polymerase chain reaction.

Results: Mean duration of RVGE in 14 patients was 13.9 days and mean severity score was 7.4. Two RV strains (G3P [8] and G2P [4]) were mainly circulating in the ward, which might result in the formation of a reassortant G2P [8] strain and mixed infection with G2+3P [8] in the immunocompromised patients. RV antigenemia was detected in 22 of the 28 patients (78.6%). RV-specific IgG titers in acute-phase sera of RVGE group were significantly lower than those in non-RVGE group (P=0.001). Mean age of the patients was significantly lower in RVGE group (5.5 ± 4.6 years) than non RVGE patients (8.0 ± 4.5 years) (P=0.015).

Conclusion: Our data demonstrate that host factors including age, underlying diseases, and immune status may be associated with the susceptibility of RV infection in immunocompromised patients at the time of the nosocomial infection.

Keywords
Rotavirus; Gastroenteritis; Antigenemia; Immunocompromised patients

Introduction

Rotavirus (RV) is a major etiological agent of acute gastroenteritis (GE) in children worldwide. In each year, RV has been associated with high morbidity and mortality with an estimated 215000 deaths occurring annually under 5 years of age, mainly in developing countries [1]. In addition to gastroenteritis, RV has been reported to cause systemic complications including high fever, hepatitis [2,3], seizures [4-6], and encephalopathy [7,8]. Although the mechanisms of the complications are not fully understood, systemic infection, as evidenced by the detection of RV antigen in serum of infected children [9] and in organs of experimentally infected animals [10], might play an important role in causing the complications. A recent study has demonstrated that significantly longer duration and lower levels of RV antigenemia occurred in immunocompromised patients than immunocompetent RVGE patients [11]. However, an association between the kinetics of RV antigenemia and host factors including immune status remains unclear in RVGE patients.

RV is commonly associated with nosocomial infection, which could account for an average of 27% (14-51%) of all hospitalized cases of RVGE in developed countries [12]. Previous reports have demonstrated that the nosocomial RV infection occurred in people of all ages, including immunocompetent and immunocompromised patients [13-15]. Since RV is considered to cause more severe illness in immunocompromised patients than immunocompetent children [16,17], it is important to develop reliable strategy for preventing the nosocomial RV infection in this vulnerable population.

The purpose of this study was to determine the factors in association with the nosocomial RVGE outbreak in pediatric hematology/oncology ward and to investigate the correlation between host immune status and RV antigenemia in the immunocompromised children.

Materials and Methods

Patients and gastroenteritis outbreak

One patient (case 7) had diarrhoea from May 1, 2011, and subsequently he was diagnosed with RV infection on May 12 by using a commercial enzyme-linked immunosorbent assay (ELISA) kit at Department of Pediatrics in Nagoya University Hospital. Following this first RVGE case, same symptoms occurred in several patients. From May 16 to June 9, 2011 that was defined as the observation period of this study, a total of 28 patients (20 males and 8 females) with hematological malignancies or solid organ tumor were admitted in the pediatric hematology and oncology ward. Ages of the subjects ranged from 7 months to 19 years, with a mean of 8 years. The underlying diseases of the patients were 5 aplastic anemia, 1 hepatoblastoma, 3 malignant lymphoma, 6 neuroblastoma, 1 yolk sac tumor, 3 acute myelogenous leukemia, 1 Epstein Barr virus-associated hemophagocytic lymphohistiocytosis, 5 acute lymphoblastic leukemia, 1 Ewing sarcoma, and 2 chronic myeloid leukemia. No other patients with infectious disease were admitted to the ward during observation period. Nineteen of the 28 patients received chemotherapy for treatment of the underlying diseases and 11 of the 28 patients had received hematopoietic stem cell transplantation (HSCT) before the study period. Two patients received HSCT after chemotherapy during the observation period.
Three of the 11 transplant recipients had diarrhoea during the observation period, which was considered to be acute graft-versus-host disease. In addition, 11 immunosuppressed patients without HSCT also developed diarrhoea during the observation period. Stool samples collected from patients with gastroenteritis were tested for adenovirus by using a commercial ELISA kit (Adenocclone, Meridian Bioscience, Inc., Cincinnati, OH). Adenovirus antigen was detected in only one patient (case 28) and no bacteria were isolated from the samples.

Clinical manifestations were examined retrospectively from medical records. The severity of GE was evaluated by using a 20-point Vesikari scoring scale [18]. Laboratory findings including white blood cell (WBC), neutrophil and lymphocyte counts were examined on May 9 in all subjects for evaluation of the host immune status. Informed consent was obtained from patient's parents before enrollment of this study. This study was approved by the Ethics Committee of Fujita Health University School of Medicine. This study did not require review by the Center for Disease Control (CDC) Institutional Review Board because the CDC tested pre-existing, anonymous specimens.

Sample collection

Serum samples were collected weekly for one month of the observation period from 25 patients and collected for two weeks from 3 patients who were discharged earlier from the hospital. Stool specimens were collected weekly from 14 patients with gastrointestinal symptoms. The rectal swabs were kept in 10% phosphate buffered saline (PBS). A total of 106 serum and 44 rectal swab samples were collected from the patients and 5 serum samples were also collected from age-matched healthy children as control. All samples were stored at -70 ºC before shipping for analysis of the Viral Gastroenteritis.

Laboratory of the US CDC

ELISA for the detection of rotavirus antigenemia: RV antigen in stool and serum was measured using an in-house ELISA specific for RV VP6 [19]. To prevent potential cross-contamination of samples, stool and serum were prepared in different rooms. Briefly, 96 well plates (Nalge Nunc International, Rochester, NY) coated with a monoclonal antibody against the VP6 antigen of RV (YO-156) were blocked with 1% bovine serum albumin in PBS containing Tween 20 (PBST), washed with PBST, then incubated with 50 μl of stool extract (10% in PBS) or diluted serum (1:8 in PBS) at 4°C overnight. After washing, 50 μl of rabbit anti-human RV hyper immune serum dilute 1/5,000 with PBST containing 2.5% skim milk (MPBS) were added at 37°C for 1.5 hours. After washing, a 1:2,000 dilution of peroxidase conjugated donkey anti-rabbit IgG (Jackson Immuno Research Laboratory Inc., West Grove, PA) were added at 37°C for 1.5 hours. After adding the substrate, the optical density (OD) was read at 450 nm with an ELA reader (MRX Revelation, Dynex Technologies, Chantilly, VA). As the mean OD of the control samples was 0.142±0.017, we defined 0.194 as the mean OD of the control serum wells.

ELISA for the detection of rotavirus antibody: To evaluate role of the immune status in RV infection, RV IgA and IgG titers were examined in acute (1st week of the observation period) and convalescent sera (4th week of the observation period) collected from all hospitalized patients except for cases 26, 27 and 28. Serum collected in 2nd week was used as convalescent phase sample in the three patients because they were discharge before 4th week. Antibody titers were measured by ELISAs for RV IgG and IgA [20]. Briefly, 96 wells plates were coated overnight with rabbit hyper immune serum to RV strain RRV at 4°C. After washing and blocking with MPBS for 1 hour at 37°C, plates were incubated with supernatants of RVV-infected MA104 cells (1:10 diluted in diluent buffer) for 1 hour at 37°C. After washing, serum samples that were serially diluted from 1:10 to 1:5120 in diluent buffer were added, followed by a secondary goat anti-human IgG-biotin (1:3000) or human IgA-biotin (1:2000) (KPL Inc., Gaithersburg, MD) in MPBS for 1 hour at 37°C. After washing, extra Vidin (1:3000) (Sigma-Aldrich, St. Louis, MO) was added for 1 hour at 37°C. After adding the substrate, OD was read at 450 nm. IgG and IgA titers in serum were calculated as the reciprocal of the highest dilution that gave a mean OD greater than the cut-off value (3 standard deviations above the mean OD of the negative-control serum wells).

G and P typing and sequence analysis: G genotypes of RV in stool were determined by using reverse transcription polymerase chain reaction (RT-PCR) with previously published specific primers 9conIL and VP7-RDg [21]. The second amplification was performed from the first PCR product (1025 bp) using the 9conIL primer and a cocktail of G type-specific primers (9T-1, 9T-2, 9T-3P, 9T-4 and 9T-B) for VP7 G1 (158 bp), G2 (224 bp), G3 (466 bp), G4 (403 bp) and G9 (110 bp), respectively.

RV VP4 P typing was performed in the same manner as VP7 gene assay with previously published specific primers Con2 and Con3 [22]. The second amplification was performed from the first PCR product (877 bp) using the Con3 primer and a cocktail of P type-specific primers (2T-1, 3T-1 and 1T-1) for P4 (484 bp), P6 (268 bp) and P8 (346 bp), respectively. The PCR products of rotavirus VP7 and VP4 genes were purified by mini columns (QIAquick, Qiagen, Valencia, CA) and sequences were determined by using the ABI-PRISM Big Dye terminator Cycle Sequencing kit and an ABI Prism 310 Genetic analyzer (Applied Biosystems Inc. Foster City, CA).

Statistical analysis

Statistical analyses among clinical variables, RV antigen levels and immunoglobulin levels in serum were performed using SPSS version 20. The one way ANOVA analysis of variance by ranks procedure was employed to test mean severity scores and WBC, neutrophil, lymphocyte cell counts and duration of the admission among the patients, followed by pair-wise examinations using the Mann-Whitney U test for unpaired data. Levels of RV antigenemia and titers of RV IgA and IgG in serum of patients with or without gastroenteritis were compared using either a paired Wilcoxon signed ranks test or Mann-Whitney U test. Gender, underlying diseases, chemotherapy of patients with or without gastroenteritis during study period and HCST prior to this study were compared using Fisher’s exact probability test. In all comparisons, a p-value<0.05 (two-tailed) was considered statistically significant. Correlations among the duration of GE, RV antigen in serum samples, RV antigen in stool, total Vesikari severity score, and individual symptom scores were examined using Spearman rank correlation coefficient.

Results

RV antigen in serum and stool

Of the 28 patients admitted for chemotherapy in the hospital, one half had developed diarrhea during their stay. These 14 GE patients had a mean duration of 13.9 days and a mean Vesikari severity score of 7.4. RV antigen was detected in 29 (65.9%) of the 44 stool samples.
collected from the 14 patients with GE and in 69 (65.1%) of the 106 serum samples from 22 of the 28 patients (except cases 4, 5, 9, 19, 22, and 27) (Figure 1). Of the 22 patients with RV antigenemia, 11 had gastroenteritis (cases 3, 7, 8, 10, 11, 12, 15, 23, 24, 26, and 28) and the other 11 did not (cases 1, 2, 6, 13, 14, 16, 17, 18, 20, 21, and 25). RV antigenemia lasted for entire observational period (4 weeks) in 12 of the 22 antigenemia-positive patients (cases 1, 2, 6, 7, 10, 11, 14, 15, 20, 21, 23, and 24). RV antigenemia was not observed in the 3 patients with positive RV antigen in stool (cases 19, 22, and 27).

Serological analysis

RV IgG titer in acute phase was significantly lower in RVGE group

Figure 1: Associations between rotavirus antigens in stool (black boxes) and rotavirus antigenemia (shaded bars). White boxes indicate rotavirus antigen negative in both stool and serum samples. Stool samples were collected only if the patient had GE symptoms. Case 26 died of the underlying disease and case 27 and 28 patients were discharged during the study period.
(median, 345, range: 40–2560) than non GE group (median, 3800, range: 80–20480) (P=0.001) (Figure 2A). However, no significant difference was observed in acute phase IgA antibody titers between RVGE patients (median 87, range: 40–160) and non GE patients (median 87, range: 40–160) (P=0.910). Antibody titers were compared in paired sera obtained from patients with and without RVGE. A significant increase in RV IgG titers was demonstrated in convalescent phase samples (median, 2565 fold, range: 80–20480) in comparison to acute phase samples (median, 345 fold, range: 40–2560) from RVGE patients (P=0.022) in RVGE group (Figure 2B). In contrast to RVGE group, no significant difference was observed between acute phase RV IgG antibody titers (median 87 fold, range: 80–20480) and convalescent phase one (median 4868 fold, range: 320–20480) (P=0.310) in non RVGE group (Figure 2C). No significant difference was observed in RV IgA antibody titers between acute-phase samples and convalescent-phase samples in either RVGE or non-RV patients (date not shown).

Factors in association with RVGE

Patients’ characteristics and clinical features were compared between the RVGE patients and non-RVGE patients to elucidate factors in association with RVGE in these subjects (Table 1). Mean age of the patients was significantly lower in RVGE group (5.5±4.6 years) than non RVGE group (10.6 ± 4.5 years) (P=0.015). Gender was not associated with RVGE (P=0.103). Neither HSCT (P=1.0) nor chemotherapy (P=1.0) was associated with RVGE. No significant difference in WBC (P=0.401), neutrophil counts (P=0.511), and lymphocyte counts (P=0.352) was demonstrated between the two groups. There was no significant difference in the levels of mean (P=0.769) and maximal (P=0.872) serum RV antigen levels between 11 RVGE patients and 11 non GE patients.

Molecular epidemiological analysis in RVGE outbreak

RV antigen was detected in 29 of 44 fecal swab samples by ELISA. G and P types were determined in 12 of the 29 samples by using RT-PCR. Two strains (G3P [8] (4/17, 23.5%) and G2P [4] (4/17, 23.5%) were dominant in the analyzed samples, followed by G2P [8] (2/17, 11.8%) and mixed G2/G3P [8] (2/17, 11.8%).

Discussion

Although it has been demonstrated that RV can cause severe clinical manifestations in immunocompromised transplant recipients [23-25], few studies have been conducted to examine the full
spectrum of RV infection in these patients. Stelzmueller et al. [23]
demonstrated that RV infection was observed in 1.5% of solid organ
transplant recipients, and the highest frequency of RV infections
was observed in pediatric liver transplant recipients (52%) based
on conventional RV antigen detection analysis of stool samples. RV
infection has also been identified in 10-12% of pediatric bone marrow
transplant recipients [26,27]. In this outbreak, GE was observed in
14 of the 28 (50.0%) patients. All diarrhoeal stool samples collected
from 14 GE patients were positive for RV antigen. In addition, eleven
asymptomatic patients with RV antigenemia were identified in this
cohort. To our knowledge, this is the first study demonstrating a
high prevalence of RV antigenemia in a nosocomial RVGE outbreak
among immunosuppressed patients. Persistent RV antigenemia
observed in this outbreak corresponded with our previous data
in transplant patients [12]. Future studies are needed to elucidate
clinical implications of persistent low RV antigenemia in
immunocompromised patients.

It has been demonstrated that RV infection was more severe in
transplant recipients than immunocompetent patients [28]. In the
present study, we observed a long duration of GE (13.9 days) but a
relatively low mean Vesikari severity score of 7.4. This low severity
of GE in this cohort might be due to older age (5.5 years) of the
patients. It is highly likely that these patients had RV infection before,
which is known to protect against subsequent infection and severity
of RVGE [29,30]. Of note, the patients who did not develop RVGE
had a significantly higher mean age than those in RVGE group in this
outbreak.

From clinical perspectives, it is very important to elucidate risk
factors for RVGE in order to better prevent nosocomial infection among
immunocompromised patients in the ward. Our present study found
several possible risk factors for RVGE in this setting. First, lower titer
of RV IgG antibody and younger age appeared to be associated with
RVGE in patients. Second, tracking of the patients’ movements and
characterization of RV strains from patients in the same or nearby wards
helped us determine that the transfer of patients between the wards
might have contributed to the spread of common rotavirus strains,
the emergence of new reassortant strains, and the outbreak of this
nosocomial infection. On the other hand, we demonstrated an equally
high prevalence of antigenemia in immunocompromised patients with
or without RVGE, suggesting that antigenemia may not contribute
the expression of GE. RV strain G1P8 was the most predominant and
[31]. It has been demonstrated that introduction of RV vaccines affected
the prevalence of endemic strains in some Asian countries [32,33].
Additionally, G9P [8], G2P [4], G3P [8], G1P [4], and G6P [6] were also
detected during the period [34]. Then, G3P [8] strain emerged (65.0%)
during 2010-2011 season, and G2P [4] strain was rarely detected
(2.4%) at that time period [35]. This outbreak occurred just before
introduction of RV vaccine in Japan. Two types of RV strains G3P [8]
and G2P [4] were mainly circulating in this outbreak, which resulted in
nosocomial RVGE in almost half of the immunocompromised patients
in a pediatric hematologic/oncology ward (Table 2). It is likely that G3P
has been reported to be uncommon among healthy children in several
developed countries including Japan [35-38], we thought that strain
G2P [8] identified in this outbreak would be a reassortant between G3P

Our present study has several limitations. First, we only enrolled a
relatively small number of transplant patients in one hospital for four
weeks. Second, we did not collect stool samples from non GE patients,
hospital staff or patients’ family members. In addition, except for RV
and adenovirus we did not look for other viral pathogens that might
cause this GE outbreak as well. Although it was too small to carry
out multivariate regression analysis in this study, younger patient and
frequent movement to other wards were apparent key risk factors for
nosocomial RV infection in pediatric hematology/oncology ward. High prevalence of RV infection in transplant patients and patterns
of RV transmission in hospital wards are useful information which
should encourage scientists and clinicians to develop measures and
strategies to manage and protect this vulnerable population in health
care settings.

Acknowledgments

Potential conflicts of interest. All authors report no conflicts of interest
relevant to this article.

Financial Support: none reported.

Table 1: Characteristics and clinical features of the patients.

<table>
<thead>
<tr>
<th>Categories</th>
<th>Rotavirus gastroenteritis</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n=14)</td>
<td>No (n=14)</td>
</tr>
<tr>
<td>Age (year)</td>
<td>5.5 ± 4.6</td>
<td>10.6 ± 4.5</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>HSCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Done</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>ND</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Chemotherapy Receiving</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Not receiving</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>WBC (&gt;10^9/L)</td>
<td>2.4 ± 1.7</td>
<td>4.0 ± 4.5</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>1.3 ± 1.3</td>
<td>2.5 ± 3.7</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td>0.83 ± 5.6</td>
<td>1.3 ± 1.1</td>
</tr>
<tr>
<td>RV antigenemia Mean OD</td>
<td>(n=11)</td>
<td>0.246 ± 0.087</td>
</tr>
<tr>
<td>Maximal OD</td>
<td>(n=11)</td>
<td>0.250 ± 0.096</td>
</tr>
<tr>
<td>Movement (time)</td>
<td>2.9 ± 1.4</td>
<td>1.9 ± 1.0</td>
</tr>
</tbody>
</table>

Table 2: Onset of diarrhoea and RV strains. RV strains

<table>
<thead>
<tr>
<th>Case numbers</th>
<th>Date of onset</th>
<th>May 16th</th>
<th>May 23rd</th>
<th>May 30th</th>
<th>June 6th</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>May 9th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>May 12th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>May 12th</td>
<td>G2/3P[8]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>May 12th</td>
<td>G2/3P[8]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>May 12th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>May 12th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>May 12th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>May 13th</td>
<td>G2P[4]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References


Author Affiliations

1Division of Viral Diseases, Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA
2Department of Pediatrics, Fujita Health University. The Second Teaching Hospital, 3-6-10, Otobashi Nakagawaku Nagoi-ary, 454-8509 Aichi, Japan
3Nagoya University, Nagoi, Aichi, Japan
4Fujita Health University, Aichi, Japan